### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physico-chemical properties of mexiletine, see [Table 1](#Table 1).

| **Parameter**                   | **Unit** | **Value**             | Source                            | **Description**                                              |
| :------------------------------ | -------- | --------------------- | --------------------------------- | ------------------------------------------------------------ |
| MW<sup>+</sup>                  | g/mol    | 179.26                | [DrugBank DB00379](#5-references) | Molecular weight                                             |
| pK<sub>a,base</sub><sup>+</sup> |          | 9.2                   | [DrugBank DB00379](#5-references) | Basic dissociation constant                                  |
| Solubility (pH)<sup>+</sup>     | mg/mL    | 0.54<br />(7)         | [DrugBank DB00379](#5-references) | Aqueous Solubility                                           |
| logD                            |          | 2.15 - 2.46           | [DrugBank DB00379](#5-references) | Distribution coefficient                                     |
| fu<sup>+</sup>                  | %        | 50                    | [DrugBank DB00379](#5-references) | Fraction unbound in plasma                                   |
| CYP1A2 CL                       | l/h      | 0.5 - 11              | [Labbé 2000](#5-references)       | Partial metabolic clearance of mexiletine to N-hydroxymexiletine |
| CYP2D6 CL                       | l/h      | 12 - 13               | [Labbé 2000](#5-references)       | Difference in non-renal CL between CYP2D6 extensive and poor metabolizers |
| Unspecific liver CL             | l/h      | 12 - 24               | [Labbé 2000](#5-references)       | Non-renal CL – CYP2D6 CL – CYP1A2 CL                         |
| Renal elimination<sup>+</sup>   | l/h      | 1.8<sup>+</sup> - 2.1 | [Labbé 2000](#5-references)       | Renal clearance                                              |
| Ki CYP1A2<sup>+</sup>           | µmol/l   | 0.28                  | [Wei 1991](#5-references)         | CYP1A2 inhibition constant                                   |

**Table 1:**<a name="Table 1"></a> Physico-chemical and *in-vitro* metabolization properties of mexiletine extracted from literature. *<sup>+</sup>: Value used in final model*

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on mexiletine, see [Table 2](#Table 2).

| **Source**           | Route | **Dose [mg]/**  **Schedule \*** | **Pop.**     | **Sex** | **N** | **Form.** | **Comment**                       |
| -------------------- | ------------------------------- | ------------ | ------- | --------------------------------- | --------------------------------- | --------------------------------- | -------------------- |
| [Campbell 1978](#5-references)<sup>+</sup> | i.v.   | 200                                      | HV                           | m       | 5     | solution  |              |
| [Campbell 1978](#5-references)<sup>+</sup>    | p.o.  | 200                                      | HV                           | m       | 5     | -         |                              |
| [Begg 1982](#5-references)<sup>+</sup>     | p.o.  | 333.24                                   | HV                           | m/f     | 6     | tablet    | 6 IDs                        |
| [Labbé 2000](#5-references)                   | p.o.  | 83.31 b.i.d.                             | HV                           | m/f     | 1     | -         | EM/PM                        |
| [Campbell 1978](#5-references)<sup>+</sup>    | i.v.  | 200                                      | patients                     | -       | 10    | solution  |                              |
| [Pringle 1986](#5-references)<sup>+</sup>     | p.o.  | 83.31 - 166.62 - 249.9 -  333.24 - 499.9 | HV                           | m       | 12    | capsule   |                              |
| [Kusumoto 1998](#5-references)<sup>+</sup>    | p.o.  | 166.62                                   | HV                           | m       | 9     | capsule   |                              |
| [Pentikäinen 1984](#5-references)<sup>+</sup> | i.v.  | 166.62                                   | acute myocardial  infarction | -       | 18    | solution  | acute myocardial  infarction |
| [Joeres 1987](#5-references)<sup>+</sup>      | p.o.  | 200                                      | HV                           | -       | 1     | -         |                              |

**Table 2:**<a name="Table 2"></a> Literature sources of clinical concentration data of mexiletine used for model development and validation. *\*: single dose unless otherwise specified; EM: extensive metabolizers; PM: poor metabolizers; <sup>+</sup>: Data used for final parameter identification*